Advertisement

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Opening Session Panel Discussion

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Advertisement

Advertisement

Nov

20

Today In Oncology

New Computational Tool Shows Strong Accuracy in Predicting Cancer Drug Targets

Long-Term Survival With vs Without Postmastectomy Chest Wall Irradiation in Breast Cancer

Newly Diagnosed AL Amyloidosis FDA Grants Traditional Approval to Regimen

Curative Treatment After First-Line Immunotherapy Improves Survival in HCC

FDA Approves Selumetinib for Adults With NF1 With Symptomatic, Inoperable Plexiform Neurofibromas

Advertisement

© 2025 HSP News Service, L.L.C.